CRISPR Therapeutics AG (CRSP)
↓ Download CSV- Sector Manufacturing
- Incorporated V8
- Fiscal year ends Dec 31
In fiscal 2025, CRISPR Therapeutics AG reported revenue of $3.51M, down 90.6% from the prior year. The company ran a net loss, with a net margin of -16569.8%. It held $2.27B in total assets against $343.43M in total liabilities.
Key ratios (FY2025)
-18933.6%
Operating margin
-16569.8%
Net margin
-30.3%
Return on equity
-90.6%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.51M | $37.31M | $371.21M | $1.20M | $914.96M | $719.0K | $289.59M | $3.12M | — | — |
| Operating Income | -$664.57M | -$466.57M | -$222.54M | -$673.16M | $373.53M | -$354.44M | $46.74M | -$158.94M | -$64.65M | -$68.13M |
| Net Income | -$581.60M | -$366.25M | -$153.61M | -$650.17M | $377.66M | -$348.87M | $66.86M | -$164.98M | -$68.36M | -$23.18M |
| EPS (Diluted) | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.70 | $-5.29 | $1.17 | $-3.44 | $-1.71 | — |
| Total Assets | $2.27B | $2.24B | $2.23B | $2.24B | $2.75B | $1.83B | $1.07B | $489.02M | $271.35M | $344.96M |
| Total Liabilities | $343.43M | $309.95M | $346.77M | $367.58M | $352.42M | $163.73M | $127.33M | $96.82M | $83.51M | $112.12M |
| Shareholders' Equity | $1.92B | $1.93B | $1.88B | $1.88B | $2.40B | $1.66B | $939.42M | $392.19M | $187.83M | $232.85M |
| Cash & Equivalents | $347.56M | $298.26M | $389.48M | $211.88M | $923.03M | $1.17B | $943.77M | $456.65M | $239.76M | $315.52M |
| Operating Cash Flow | -$345.01M | -$142.77M | -$260.38M | -$495.74M | $538.97M | -$238.37M | $56.68M | -$96.24M | -$70.09M | -$52.86M |
| Capital Expenditures | $914.0K | $1.90M | $9.47M | $37.19M | $81.70M | $18.36M | $6.68M | $2.77M | $7.81M | $3.02M |
| Shares Outstanding | 95.89M | 85.74M | 80.04M | 78.51M | 76.99M | 73.91M | 60.78M | 51.85M | 40.59M | 39.72M |